Lifting the mantle: unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma

The management of relapsed/refractory mantle cell lymphoma (MCL) remains a clinical challenge. A standard second-line treatment for relapsed/refractory MCL does not exist. Management of relapsed/refractory MCL requires an individualized treatment approach, incorporating factors such as: functional status, prior treatments, response to prior therapies, and disease biology. Generally, there are two categories of salvage therapy; the first, non-cross-resistant cytotoxic chemotherapeutic agents and, the second, pathway-targeted agents.

Source: Blood Reviews - November 1, 2014 Category: Hematology Authors: Alberto Mussetti, Anita Kumar, Parastoo B. Dahi, Miguel-Angel Perales, Craig S. Sauter Tags: Review Source Type: research